Dr. Robert Montgomery, a pioneering transplant surgeon, survived multiple life-threatening cardiac arrests before receiving a heart transplant in 2018, a procedure that later enabled him to lead groundbreaking advances in organ transplantation. His journey from patient to innovator underscores the evolving landscape of transplant medicine amid ongoing organ shortages.
Montgomery’s heart condition, dilated cardiomyopathy—a disease causing the heart chambers to enlarge and weaken—was first revealed in his teenage years following the sudden death of his brother from the same inherited condition. Despite the challenges his diagnosis posed to a demanding surgical career, Montgomery embarked on a path to revolutionize organ transplantation, driven by personal experience and a commitment to expanding access to lifesaving organs.
Early in his career at Johns Hopkins Medicine, Montgomery focused on kidney transplants, where he developed minimally invasive techniques for living donors and pioneered paired kidney exchanges. This approach involved swapping kidneys between incompatible donor-recipient pairs, sometimes in extended donation chains, effectively increasing the pool of available organs. His team achieved national recognition for conducting an eight-way kidney exchange surgery in a single day.
Montgomery also played a key role in expanding transplant options for HIV-positive patients, advocating for the use of kidneys from donors with HIV—a practice that required changes in federal law and is now standard care. Throughout his career, he was known for pushing boundaries, often facing skepticism for proposing innovative but unproven strategies.
Despite his expertise, Montgomery’s own health rapidly declined. In 2018, after experiencing multiple cardiac arrests, including one during a Broadway show, Montgomery was admitted to NYU Langone Health, where he had been recruited to establish a leading transplant program. His critical condition qualified him for the heart transplant waiting list, though such organs are in extraordinarily short supply.
On September 20, 2018, he received a donor heart from a person who had died of a heroin overdose and was infected with hepatitis C. Although the transplant involved considerable risk and required participation in a clinical trial, Montgomery accepted the organ based on his belief in expanding donor criteria, noting that hepatitis C infections can now be effectively treated. Following a six-hour surgery, he recovered swiftly and resumed clinical work within days.
Recognizing the persistent scarcity of human donor organs, Montgomery turned toward xenotransplantation — the transplantation of animal organs into humans. In 2021, his team conducted the first successful kidney transplant from a genetically modified pig into a brain-dead human patient, with the organ functioning without rejection. This landmark procedure demonstrated the potential for pig organs to serve as viable alternatives in human transplantation.
Subsequent experiments involving pig kidney and heart transplants into terminally ill patients further revealed that genetically engineered porcine organs could survive in the human body without triggering destructive immune responses, despite the patients’ underlying illnesses. Last year, the U.S. Food and Drug Administration approved clinical trials of pig organ transplants for very ill patients with limited options, with Montgomery leading two such trials.
Since his transplant, Montgomery has resumed an active professional and personal life. He maintains a rigorous daily routine to protect his new heart, including morning walks, and has traveled extensively with his family. His work continues to influence transplant medicine, offering hope for expanded organ availability through innovative surgical techniques and xenotransplantation research.